Anti-CD70 Antibody [Bu69] (A279907)

Anti-CD70 Antibody [Bu69]

Mouse monoclonal [Bu69] antibody to CD70.

This antibody recognises human CD70, also known as CD27 ligand (CD27-L) or Tumor necrosis factor ligand superfamily member 7. CD70 is a 193 amino acid ~29 kDa single pass type II transmembrane glycoprotein belonging to the tumour necrosis factor (TNF) family (UniProt: P32970).CD70 is expressed on a small number of activated T-cells and the majority of activated B-cells. Interaction of CD70 with its receptor, CD27, is thought to play an important role in lymphocyte activation, proliferation, survival and differentiation. Mouse anti Human CD70 antibody, clone Bu69 has been used for the inhibition of neural stem cell induced apoptosis of allogeneic T cells in vitro.

Flow Cytometry, IHC-Fr

Flow Cytometry: 1:50 - 1:200, Use 10µl of the suggested working dilution to label 10⁶ cells in 100µl

Human

Mouse

Monoclonal

Bu69

IgG1

1 mg/ml

Liquid

Supplied in Phosphate Buffered Saline with 0.09% Sodium Azide.

Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.

Mouse anti Human CD70 antibody, clone Bu69 recognises human CD70, also known as CD27 ligand (CD27-L) or Tumor necrosis factor ligand superfamily member 7. CD70 is a 193 amino acid ~29 kDa single pass type II transmembrane glycoprotein belonging to the tumour necrosis factor (TNF) family (UniProt: P32970).CD70 is expressed on a small number of activated T-cells and the majority of activated B-cells (Bowman et al. 1994). Interaction of CD70 with its receptor, CD27, is thought to play an important role in lymphocyte activation, proliferation, survival and differentiation (Hintzen et al. 1994).Mouse anti Human CD70 antibody, clone Bu69 has been used for the inhibition of neural stem cell induced apoptosis of allogeneic T cells in vitro (Lee et al. 2013).